More reasons to use SGLT2 inhibitors: EMPEROR-reduced and DAPA-CKD
- PMID: 33068607
- DOI: 10.1016/j.kint.2020.10.002
More reasons to use SGLT2 inhibitors: EMPEROR-reduced and DAPA-CKD
Keywords: cardiovascular death; end-stage kidney disease; heart failure; nondiabetic kidney disease.
Comment on
-
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28. N Engl J Med. 2020. PMID: 32865377 Clinical Trial.
-
Dapagliflozin in Patients with Chronic Kidney Disease.N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. N Engl J Med. 2020. PMID: 32970396 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical